{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T14:30:26Z","timestamp":1790605826907,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.nationalarchives.gov.uk\/doc\/open-government-licence\/version\/3\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009032","name":"Pfizer Limited","doi-asserted-by":"publisher","award":["73604909"],"award-info":[{"award-number":["73604909"]}],"id":[{"id":"10.13039\/100009032","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.vaccine.2025.127647","type":"journal-article","created":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T17:43:41Z","timestamp":1755971021000},"page":"127647","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Understanding the immunity gap for serogroup B invasive meningococcal disease due to non-pharmaceutical interventions during the Covid-19 pandemic"],"prefix":"10.1016","volume":"63","author":[{"given":"Jennifer","family":"Louth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Holland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe","family":"Chum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Tonge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezra","family":"Linley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Lucidarme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen A.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ray","family":"Borrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.vaccine.2025.127647_bb0005","first-page":"483","article-title":"The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination","volume":"81","author":"Parikh","year":"2020","journal-title":"J Inf Secur"},{"key":"10.1016\/j.vaccine.2025.127647_bb0010","author":"United Kingdom Health Security Agency"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127647_bb0015","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S2352-4642(22)00379-0","article-title":"Outcomes of meningococcal serogroup B disease in children after implementation of routine infant 4CMenB vaccination in England: an active, prospective, national surveillance study","volume":"7","author":"Mensah","year":"2023","journal-title":"Lancet Child Adolesc Health"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127647_bb0020","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2024.2357924","article-title":"4CMenB journey to the 10-year anniversary and beyond","volume":"20","author":"Abitbol","year":"2024","journal-title":"Hum Vaccin Immunother"},{"issue":"9","key":"10.1016\/j.vaccine.2025.127647_bb0025","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.3201\/eid2709.204866","article-title":"Invasive meningococcal disease, 2011-2020, and impact of the COVID-19 pandemic, England","volume":"27","author":"Subbarao","year":"2021","journal-title":"Emerg Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2025.127647_bb0030","first-page":"e582","article-title":"Trends in invasive bacterial diseases during the first 2 years of the COVID-19 pandemic: analyses of prospective surveillance data from 30 countries and territories in the IRIS consortium. Lancet digit","volume":"5","author":"Shaw","year":"2023","journal-title":"Health"},{"issue":"5","key":"10.1016\/j.vaccine.2025.127647_bb0035","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.idnow.2021.05.004","article-title":"Pediatric infectious disease group (GPIP) position paper on the immune debt of the COVID-19 pandemic in childhood, how can we fill the immunity gap?","volume":"51","author":"Cohen","year":"2021","journal-title":"Infect Dis Now"},{"issue":"12","key":"10.1016\/j.vaccine.2025.127647_bb0040","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/S2352-4642(24)00236-0","article-title":"The pattern of childhood infections during and after the COVID-19 pandemic","volume":"8","author":"Nygaard","year":"2024","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1016\/j.vaccine.2025.127647_bb0045","article-title":"Surge of pediatric respiratory tract infections after the COVID-19 pandemic and the concept of \u201cimmune debt\u201d","volume":"21","author":"Lenglart","year":"2024","journal-title":"J Pediatr"},{"key":"10.1016\/j.vaccine.2025.127647_bb0050","first-page":"ciae493","article-title":"Cycles of susceptibility: immunity debt explains altered infectious disease dynamics post -pandemic","volume":"11","author":"Munro","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"24","key":"10.1016\/j.vaccine.2025.127647_bb0070","doi-asserted-by":"crossref","first-page":"5093","DOI":"10.1016\/j.vaccine.2006.03.091","article-title":"Neisseria meningitidis group B correlates of protection and assay standardization--international meeting report Emory University, Atlanta, Georgia, United States, 16\u201317 March 2005","volume":"24","author":"Borrow","year":"2006","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2025.127647_bb0075","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1128\/CVI.00102-07","article-title":"Seroprevalence of bactericidal and anti-outer membrane vesicle antibodies to Neisseria meningitidis group B in England","volume":"14","author":"Trotter","year":"2007","journal-title":"Clin Vaccine Immunol"},{"issue":"5","key":"10.1016\/j.vaccine.2025.127647_bb0080","first-page":"385","article-title":"Epidemiological and strain characteristics of invasive meningococcal disease prior to, during and after COVID-19 pandemic restrictions in England","volume":"87","author":"Clark","year":"2023","journal-title":"J Inf Secur"},{"key":"10.1016\/j.vaccine.2025.127647_bb0085","first-page":"169","volume":"2019","author":"Lucidarme","year":"1969","journal-title":"Methods Mol Biol"},{"issue":"7","key":"10.1016\/j.vaccine.2025.127647_bb0095","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1097\/INF.0b013e318292f425","article-title":"Seroprevalence and placental transmission of maternal antibodies specific for Neisseria meningitidis serogroups a, C, Y and W135 and influence of maternal antibodies on the immune response to a primary course of MenACWY-CRM vaccine in the United Kingdom","volume":"32","author":"Blanchard-Rohner","year":"2013","journal-title":"Pediatr Infect Dis J"},{"issue":"12","key":"10.1016\/j.vaccine.2025.127647_bb0100","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1080\/21645515.2019.1627159","article-title":"Persistence of the immune response after 4CMenB vaccination, and the response to an additional booster dose in infants, children, adolescents, and young adults","volume":"15","author":"Martin\u00f3n-Torres","year":"2019","journal-title":"Hum Vaccin Immunother"},{"issue":"151","key":"10.1016\/j.vaccine.2025.127647_bb0105","article-title":"Modelling the impact of COVID-19 and routine MenACWY vaccination on meningococcal carriage and disease in the UK","volume":"1","author":"Hadley","year":"2023","journal-title":"Epidemiol Infect"},{"issue":"4","key":"10.1016\/j.vaccine.2025.127647_bb0110","first-page":"183","article-title":"Carriage of Neisseria meningitidis in newly enlisted young military professionals during the COVID-19 pandemic","volume":"71","author":"Sir\u00e1kov\u00e1","year":"2022","journal-title":"Epidemiol Mikrobiol Imunol"},{"issue":"4","key":"10.1016\/j.vaccine.2025.127647_bb0115","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/INF.0000000000004622","article-title":"The prevalence, serogroup distribution and risk factors of meningococcal carriage in children, adolescents and young adults in Turkey Meningo-Carr-TR study PART 3: COVID-19 pandemic situation","volume":"44","author":"Kizil","year":"2025","journal-title":"Pediatr Infect Dis J"},{"issue":"5","key":"10.1016\/j.vaccine.2025.127647_bb0120","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S1473-3099(20)30842-2","article-title":"Meningococcal carriage in periods of high and low invasive meningococcal disease incidence in the UK: comparison of UKMenCar1-4 cross-sectional survey results","volume":"21","author":"MacLennan","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"9960","key":"10.1016\/j.vaccine.2025.127647_bb0125","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/S0140-6736(14)60842-4","article-title":"Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial","volume":"384","author":"Read","year":"2014","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127647_bb0130","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1017\/S0950268805005339","article-title":"The natural history of meningococcal carriage and disease","volume":"134","author":"Trotter","year":"2006","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2025.127647_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104493","article-title":"The COVID-19 pandemic as an opportunity for unravelling the causative association between respiratory viruses and pneumococcus-associated disease in young children: a prospective study","volume":"90","author":"Dagan","year":"2023","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127647_bb0140","doi-asserted-by":"crossref","first-page":"e1154","DOI":"10.1093\/cid\/ciab1014","article-title":"Decline in pneumococcal disease in young children during the coronavirus disease 2019 (COVID-19) pandemic in Israel associated with suppression of seasonal respiratory viruses, despite persistent pneumococcal carriage: a prospective cohort study","volume":"75","author":"Danino","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"8766","key":"10.1016\/j.vaccine.2025.127647_bb0150","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/0140-6736(91)91112-8","article-title":"Influenza a and meningococcal disease","volume":"338","author":"Cartwright","year":"1991","journal-title":"Lancet"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25009442?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25009442?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T14:55:57Z","timestamp":1772808957000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25009442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":25,"alternative-id":["S0264410X25009442"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127647","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Understanding the immunity gap for serogroup B invasive meningococcal disease due to non-pharmaceutical interventions during the Covid-19 pandemic","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127647","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"127647"}}